Susquehanna International Group
ADCT icon

Susquehanna International Group’s ADC Therapeutics ADCT Stock Holding History

Susquehanna International Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,800
Closed -$195K – 12200
2025
Q3 		$195K Sell
48,800
-8,200
-14% -$25.8K ﹤0.01% 11020
2025
Q2 		$153K Buy
+57,000
New +$120K ﹤0.01% 11484
2025
Q1 		– Sell
-28,900
Closed -$57.5K – 12378
2024
Q4 		$57.5K Buy
+28,900
New +$75.6K ﹤0.01% 11621
2024
Q3 		– Sell
-30,800
Closed -$97.3K – 11861
2024
Q2 		$97.3K Buy
30,800
+2,000
+7% +$7.95K ﹤0.01% 11044
2024
Q1 		$129K Buy
+28,800
New +$106K ﹤0.01% 11036
2022
Q4 		– Sell
-29,500
Closed -$142K – 12269
2022
Q3 		$142K Buy
+29,500
New +$214K ﹤0.01% 11313
2022
Q1 		– Sell
-51,100
Closed -$1.03M – 12883
2021
Q4 		$1.03M Buy
51,100
+1,900
+4% +$45.8K ﹤0.01% 7211
2021
Q3 		$1.34M Sell
49,200
-2,300
-4% -$58.9K ﹤0.01% 6795
2021
Q2 		$1.25M Sell
51,500
-19,000
-27% -$441K ﹤0.01% 7125
2021
Q1 		$1.72M Buy
70,500
+51,400
+269% +$1.49M ﹤0.01% 6283
2020
Q4 		$611K Buy
19,100
+8,900
+87% +$292K ﹤0.01% 7847
2020
Q3 		$336K Buy
+10,200
New +$441K ﹤0.01% 8473

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's ADCT Position: Q1 2026 in Review

Susquehanna International Group increased its ADC Therapeutics (ADCT) stake by 278% in Q1 2026, buying an estimated $221K and bringing the position to 76,268 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #10965.

Susquehanna International Group first reported a position in ADCT in Q4 2020 and has held it in 15 quarters since. The position peaked at $2.42M in Q1 2021. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Susquehanna International Group held 76,268 shares of ADC Therapeutics worth $286K as of Q1 2026.
  • Susquehanna International Group bought 56,090 ADC Therapeutics shares in Q1 2026, an estimated $221K.
  • ADC Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10965 holding.
  • Susquehanna International Group first reported a position in ADC Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Susquehanna International Group's ADC Therapeutics position peaked at $2.42M in Q1 2021.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.